Clinical trial · Observational
Study on the Association of GSTP1 and Other Gene Polymorphisms With Platinum-induced Myelosuppression
NCT06140082CI-TRIAL-00071427unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study intends to design a retrospective and prospective, cohort study to explore the association between genetic polymorphism of GSTP1 A313G rs1695 or others and adverse effects of platinum drugs, aiming to explore the risk factors of myelosuppression caused by platinum drugs, and provide data support for optimizing anti-tumor chemotherapy regimen, improve medication safety and improve the compliance of chemotherapy in patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| GSTP1 A313G （AA） | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Gene mutation-type group
- description
- According to the characteristics of the patient's own disease, the clinician develops the corresponding medication regimen, and the patient uses one of the target drugs, cisplatin/carboplatin/nedaplatin/loplatin, or other regimen containing the target drug. Peripheral blood of patients was collected, genetic testing was performed, GSTP1 mutant (AG/GG) was classified into this group, and the time and degree of myelosuppression in this group were recorded.
- label
- Gene wild-type group
- description
- According to the characteristics of the patient's own disease, the clinician develops the corresponding medication regimen, and the patient uses one of the target drugs, cisplatin/carboplatin/nedaplatin/loplatin, or other regimen containing the target drug. Peripheral blood of patients was collected for genetic testing, GSTP1 wild type (AA) was classified into this group, and the time and degree of myelosuppression in this group were recorded.
- interventionNames
- Genetic: GSTP1 A313G （AA）
Primary outcomes (1)
- measure
- Incidence of myelosuppression (≤150 days)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1. Patients with non-small cell lung cancer with clear imaging or pathological evidence 2. Using a chemotherapy regimen containing platinum 3. Conducted blood routine and biochemical tests 4. Signed informed consent Exclusion Criteria: 1. Blood routine and other relevant tests were not performed 2. Suffering from primary bone marrow system disease 3. Other reasons for not meeting the experimental requirements
References
Publications (0)
Data not yet available
No reference posted for this study.